Arrhythmias & electrophysiology
Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation
Authors' conclusion
A collaborative hybrid ablation approach to treating PersAF/LSPersAF is safe and effective.
Study context
- Population
- Adults 18 to 75 years with symptomatic persistent or longstanding persistent AF refractory to ≥1 Class I/III antiarrhythmic drug and ≤2 previous failed endocardial catheter ablation (ECAs)85 analysed for effectiveness
- Participants
- 90 adults
- Outcome
- Freedom from documented AF/atrial flutter/atrial tachycardia episodes >30 seconds, absent Class I/III antiarrhythmic drugs (except previously failed drugs at doses not exceeding those previously failed)
- Follow-up
- 12 months
Methodological detailsprospective, multicentre, investigational device exemption, Enrolment February 2015 to December 2020
- Prospective
- Multicentre
- Investigational device exemption
- Enrolment February 2015 to December 2020
Main finding
As reported in the abstract
Freedom from documented AF/atrial flutter/atrial tachycardia >30 s off Class I/III antiarrhythmic drugs
- Primary effectiveness, 61/85
- 71.8%
- 95% CI
- 62.2%-81.3%
- vs performance goal
- P=0.0134
Observational data: associations, not effects.
Further findings
Primary effectiveness · 2 years
- Primary effectiveness, 53/85
- 62.4%
- 95% CI
- 52.1%-72.7%
Safety
Composite device/procedure-related SAEs (30 days after epicardial, 7 days after endocardial ablation)
- Composite SAE rate, 6/90
- 6.7%
- 95% CI
- 2.5%-13.9%
- vs safety goal
- P < 0.001
- SAEs within 30 days of epicardial procedure
- 3
- SAEs within 7 days of endocardial procedure
- 3
- All anticoagulated at time of event
Original publication
Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation. Circ Arrhythm Electrophysiol. Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →